GROUNDBREAKING NEW WAY OF FIGHTING BACTERIAL INFECTIONS
Antimicrobial Resistance (AMR)
RISING OF
ANTIBIOTIC
RESISTANCE
Antibiotic resistance is one of the biggest threats to global
health, food security, and development today.
Misuse and overuse of antibiotics in people and animals is contributing to the development of highly resistant bacteria. The WHO predicts that by the year 2050, AMR could kill 10 million people a year.
SPECIFIC
SAFE
ALTERNATIVE
ECOLOGICAL
Biotechnology
WHAT WE DO
As the growth of resistance prompts pharma to move increasingly beyond chemical antibiotics in a search for new methods of combating bacterial infections, Alytix will be well placed to deliver a new approach. Alytix develops solutions based on bacteriophage technology for control and treatment of bacterial infections.
Bacteriophages are naturally occurring viruses that are specific for bacteria. As well as being safe, bacteriophages self-replicate, and could be dosed in low quantities and then scale up in the presence of infection.
PHAGE
PLATFORM
As the growth of resistance prompts pharma to move increasingly beyond chemical antibiotics in a search for new methods of combating bacterial infections, Alytix will be well placed to deliver a new approach.
Alytix develops solutions based on bacteriophage technology for control and treatment of bacterial infections. Bacteriophages are naturally occurring viruses that are specific for bacteria. As well as being safe, bacteriophages self-replicate, and could be dosed in low quantities and then scale up in the presence of infection.
Animal health
The overuse of antibiotics in livestock for growth promotion, weight gain and to treat, control and prevent disease has been highlighted as one of the biggest factor in the emergence of antibiotic-resistant bacteria.
In the early stage the company was focused in the development of phage cocktails for use in veterinary medicine, infectious diarrhea in calves, bovine mastitis, porcine colibacilosis and salmonellosis in poultry.
- Estimates of antibiotic use in the USA state that 70-80% of antibiotics are sold for use in animals.
Human health
The phenomenon of antibiotic-resistance in pathogenic microorganisms represents a worldwide hot-spot in the healthcare since new antibiotic-resistant strains are emerging at a constant rate and traditional treatments, based on antibiotic therapy, are now failing. The search of new alternatives is thus necessary and mandatory.
Alytix is focused on the develop of a cocktail of phages to treat Methicillin-resistant Staphylococcus aureus (MRSA) infection, and we have a wide range of formulations in our pipeline.
Meet scientists
Experienced team
We gather more than 10 years of experience working whit bacteria and phage that is now an asset at the company.
We are collaborating with diverse research group and companies. Entrepreneur & multidisciplinary team that understand management of R&D as a business with a unique view for speedup and de-risk the product development.
Marcelo Salame
CEO & Co-Founder
Exequiel Dunand
CSO & Co-Founder
Enzo F. Zamboni
President & Co-Founder
Advisors
Marcelo Grabois
Industrial Property Strategy.
Andrea Quiberoni
PhD – Independent Research Scientist of CONICET.